thalidomide has been researched along with Activated Protein C Resistance in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Activated Protein C Resistance: A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Venous thromboembolism (VTE) is a major complication of myeloma therapy recently observed with the increasing use of up-front thalidomide and dexamethasone (thal-dex)." | 9.14 | Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. ( Catalano, L; Cavo, M; Cini, M; Gozzetti, A; Legnani, C; Masini, L; Palareti, G; Patriarca, F; Tacchetti, P; Tosi, P; Valdré, L; Zamagni, E, 2010) |
| "The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism." | 7.75 | Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009) |
| "Venous thromboembolism (VTE) is a major complication of myeloma therapy recently observed with the increasing use of up-front thalidomide and dexamethasone (thal-dex)." | 5.14 | Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. ( Catalano, L; Cavo, M; Cini, M; Gozzetti, A; Legnani, C; Masini, L; Palareti, G; Patriarca, F; Tacchetti, P; Tosi, P; Valdré, L; Zamagni, E, 2010) |
| " We report the results of a prospective randomized trial of 62 newly diagnosed MM patients tested at baseline for hypercoagulability and treated with intensive chemotherapy with or without thalidomide in a randomized fashion." | 5.10 | Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. ( Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fassas, A; Fink, L; Mehta, P; Morris, C; Saghafifar, F; Siegel, E; Toor, A; Tricot, G; Whitfield, D; Zangari, M, 2002) |
| "The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism." | 3.75 | Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009) |
| "Among hematologic malignancies, multiple myeloma (MM) confers a high risk of developing such complications, with a VTE rate of nearly 10%." | 1.37 | Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. ( Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maximiliano, CL | 1 |
| Jaime, GC | 1 |
| Armando, VL | 1 |
| Vega, IL | 1 |
| Victoria, HG | 1 |
| Erika, MH | 1 |
| Talamo, GP | 1 |
| Ibrahim, S | 1 |
| Claxton, D | 1 |
| Tricot, GJ | 1 |
| Fink, LM | 1 |
| Zangari, M | 2 |
| Cini, M | 1 |
| Zamagni, E | 2 |
| Valdré, L | 1 |
| Palareti, G | 1 |
| Patriarca, F | 1 |
| Tacchetti, P | 2 |
| Legnani, C | 1 |
| Catalano, L | 1 |
| Masini, L | 1 |
| Tosi, P | 1 |
| Gozzetti, A | 1 |
| Cavo, M | 2 |
| Brioli, A | 1 |
| Zannetti, B | 1 |
| Pantani, L | 1 |
| Saghafifar, F | 1 |
| Anaissie, E | 1 |
| Badros, A | 1 |
| Desikan, R | 1 |
| Fassas, A | 1 |
| Mehta, P | 1 |
| Morris, C | 1 |
| Toor, A | 1 |
| Whitfield, D | 1 |
| Siegel, E | 1 |
| Barlogie, B | 1 |
| Fink, L | 1 |
| Tricot, G | 1 |
2 trials available for thalidomide and Activated Protein C Resistance
| Article | Year |
|---|---|
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Topics: Activated Protein C Resistance; Adult; Aged; Anticoagulants; Case-Control Studies; Dexamethasone; Fa | 2010 |
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Topics: Activated Protein C Resistance; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood C | 2002 |
3 other studies available for thalidomide and Activated Protein C Resistance
| Article | Year |
|---|---|
Mechanisms Contributing to Acquired Activated Protein C Resistance in Patients Treated with Thalidomide: A Molecular Dynamics Study.
Topics: Activated Protein C Resistance; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; | 2023 |
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Che | 2009 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethas | 2011 |